Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer
Titel:
Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and/or metastatic head and neck cancer
Auteur:
Cohen, E.E.W. Licitra, L.F. Burtness, B. Fayette, J. Gauler, T. Clement, P.M. Grau, J.J. del Campo, J.M. Mailliez, A. Haddad, R.I. Vermorken, J.B. Tahara, M. Guigay, J. Geoffrois, L. Merlano, M.C. Dupuis, N. Krämer, N. Cong, X.J. Gibson, N. Solca, F. Ehrnrooth, E. Machiels, J.-P.H.